Professor Tina Vilsbøll
Professor Tina Vilsbøll
Director, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark
Verified email at dadlnet.dk
Title
Cited by
Cited by
Year
Liraglutide and cardiovascular outcomes in type 2 diabetes
SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ...
New England Journal of Medicine 375 (4), 311-322, 2016
45802016
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ...
N Engl J Med 375, 1834-1844, 2016
30422016
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst
Diabetes 50 (3), 609-613, 2001
10842001
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud
Bmj 344, 2012
8372012
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, AG Juul, JJ Holst
The Journal of Clinical Endocrinology & Metabolism 88 (6), 2706-2713, 2003
5942003
Incretins, insulin secretion and type 2 diabetes mellitus
T Vilsbøll, JJ Holst
Diabetologia 47 (3), 357-366, 2004
5922004
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsbøll, T Krarup, S Madsbad, J Holst
Diabetologia 45 (8), 1111-1119, 2002
5832002
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of …
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, JP Courrèges, ...
Diabetes care 30 (6), 1608-1610, 2007
5812007
The incretin system and its role in type 2 diabetes mellitus
JJ Holst, T Vilsbøll, CF Deacon
Molecular and cellular endocrinology 297 (1-2), 127-136, 2009
5662009
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ...
New England Journal of Medicine 381 (9), 841-851, 2019
5412019
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsbøll, H Agersø, T Krarup, JJ Holst
The Journal of Clinical Endocrinology & Metabolism 88 (1), 220-224, 2003
5132003
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
T Vilsbøll, T Krarup, S Madsbad, JJ Holst
Regulatory peptides 114 (2-3), 115-121, 2003
4472003
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ...
Diabetes 56 (8), 1951-1959, 2007
4112007
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T Vilsbøll, J Rosenstock, H Yki‐Järvinen, WT Cefalu, Y Chen, E Luo, ...
Diabetes, Obesity and Metabolism 12 (2), 167-177, 2010
3722010
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with …
PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ...
Diabetologia 52 (2), 199-207, 2009
3382009
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen, P Alexandersen, NH Bjarnason, T Vilsbøll, B Hartmann, ...
Journal of Bone and Mineral Research 18 (12), 2180-2189, 2003
3162003
Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 …
T Vilsbøll, B Brock, H Perrild, K Levin, HH Lervang, K Kølendorf, T Krarup, ...
Diabetic Medicine 25 (2), 152-156, 2008
2672008
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
KJ Hare, T Vilsbøll, M Asmar, CF Deacon, FK Knop, JJ Holst
Diabetes 59 (7), 1765-1770, 2010
2542010
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of …
T Vilsbøll, FK Knop, T Krarup, A Johansen, S Madsbad, S Larsen, ...
The Journal of Clinical Endocrinology & Metabolism 88 (10), 4897-4903, 2003
2542003
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop
Diabetes 60 (12), 3103-3109, 2011
2482011
The system can't perform the operation now. Try again later.
Articles 1–20